This trend together with the observed association of SIPL1 copy number increase with reducing survival of patients with ER+ BC (Fig 3B) support the notion that elevation of SIPL1 expression compromised the survival of patients with PR+ and ER+ breast cancer. Here, SHARPIN is linked to breast carcinoma.